Maithel, Shishir K.
Keilson, Jessica M.
Cao, Hop S. Tran
Rupji, Manali
Mahipal, Amit
Lin, Bruce S.
Javle, Milind M.
Cleary, Sean P.
Akce, Mehmet
Switchenko, Jeffrey M.
Rocha, Flavio G.
Funding for this research was provided by:
Bristol-Myers Squibb
Article History
Received: 9 March 2023
Accepted: 15 May 2023
First Online: 27 June 2023
Disclosure
: Flavio G. Rocha, MD: Consultant for Medtronic; Research funding from Gunze; Advisory board member at Astra Zeneca. Bruce S. Lin, MD: Consultant for Exelixis, QED/Helsinn, Pfizer, Bayer, Daiichi-Sankyo; Clinical research support for Exelixis, Zymeworks, Merck, Incyte, Relay Therapeutics. Sean P. Cleary, MD: Consultant for Ethicon. Mehmet Akce, MD: Research funding (to institution) from Tesaro, RedHill Biopharma Limited, Polaris, Bristol-Myers Squibb-Ono Pharmaceutical, Xencor, Merck Sharp & Dohme, Eisai, GSK. Consulting or advisory role at Eisai, Ipsen, Exelixis, GSK, QED, Isofol, Curio Science, AsrtraZeneca, Genentech. Shishir K. Maithel, MD: Research support for clinical trials for Bristol-Myers Squibb. Milind M. Javle, MD: Research funding (to institution) from Merck, EMD Serono, Novartis, Eli Lilly, Astra Zeneca, Genentech, Transthera, Meclun, BMS, Incyte, QED, Taiho, Servier, Oncosil, Basilea, Nucana and to self or as advisory board/ DSMB member from Incyte, Zymeworks, Mundi Pharma, Nucana, MORE health, Agios, Servier, Helsinnn, Transthera, and Origimed.